Nanocrystal Delivery of Hydrophobic Anticancer Drugs

疏水性抗癌药物的纳米晶体递送

基本信息

批准号：
7903676
负责人：
Frank Bedu-Addo
金额：
$ 17.43万
依托单位：
PDS BIOTECHNOLOGY CORPORATION
依托单位国家：
美国
项目类别：
财政年份：
2010
资助国家：
美国
起止时间：
2010-09-01 至 2012-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7903676
关键词：
Acute Adverse effects Animals Antineoplastic Agents Artificial nanoparticles Behavior Biodistribution Biological Blood Circulation Camptothecin Clinical Trials Complex Cremophor Cyclodextrins Data Dendrimers Development Devices Dose Drug Carriers Drug Delivery Systems Drug Formulations Drug Industry Drug Kinetics Encapsulated Equipment Excipients Exhibits Goals Human In Vitro Industry Intravenous Investigation Kinetics Laboratory Research Lead Legal patent Lethal Dose 50 Lipids Liposomes Liver Malignant neoplasm of lung Maximum Tolerated Dose Medicine Methods Micelles Modeling Mus Nanotechnology Nanotubes North Carolina Nucleotides Oral Administration Paclitaxel Peptides Phagocytes Pharmaceutical Preparations Pharmacologic Substance Phase Pluronics Procedures Process Production Property Protocols documentation Recombinant Proteins Research Shapes Site Small Business Technology Transfer Research Solid Sonication Speed Structure Technology Therapeutic Therapeutic Effect Toxic effect Universities Vaccines base cancer therapy commercialization cost effective cost effectiveness high throughput screening improved in vivo intravenous injection large scale production malignant breast neoplasm milligram nanocrystal nanodrug nanomaterials nanoparticle nanosystems novel particle pressure public health relevance retinal rods scale up success tool tumor tumor growth uptake

项目摘要

DESCRIPTION (provided by applicant): Nanosystems have been extensively investigated for drug delivery; however, there is a challenge in transferring nanotechnology from research laboratories into pharmaceutical industry. The scientific basis for this proposal originated from our three-phase nanoparticle engineering (3PNE) method recently developed which includes phase 1, amorphous precipitate; phase 2, hydrated amorphous aggregate; and phase 3, stabilized nanocrystals (NCs). The 3PNE has been applied to the development of nanocrystals for the effective delivery of the anticancer drug, Paclitaxel (PTX). This nanocrystal is unique in its simplicity, low toxicity and its high drug loading ratio. The goal of this application is to further explore this novel nanotechnology and its feasibility for commercialization for intravenous PTX delivery. To achieve this goal, the following aims are proposed. Aim 1: Develop a technology to pave the way for large scale production of PTX nanocrystals. Aim 2: Characterize the PTX nanocrystals for their pharmaceutical kinetics, bio-distribution and acute toxicity in animals. Aim 3: Establish targeted PTX nanocrystals to further increase the anti-tumor efficiency. We believe that the success of this project will accelerate the commercialization of this nanotechnology for cancer therapy. PUBLIC HEALTH RELEVANCE: Paclitaxel nanocrystals developed using the novel three-phase nanoparticle engineering (3PNE) technology have significant potential for commercialization due to their simplicity, low toxicity, and cost effectiveness. The technology lowers drug dosing and improves efficacy.

描述（由申请人提供）：纳米系统已被广泛研究用于药物输送；然而，将纳米技术从研究实验室转移到制药行业面临着挑战。该提议的科学依据源于我们最近开发的三相纳米粒子工程（3PNE）方法，其中包括第一相，无定形沉淀；第2相，水合无定形骨料；第三相，稳定纳米晶体 (NC)。 3PNE 已应用于纳米晶体的开发，以有效输送抗癌药物紫杉醇 (PTX)。这种纳米晶体的独特之处在于其简单、低毒和高载药率。本申请的目标是进一步探索这种新型纳米技术及其静脉 PTX 输送商业化的可行性。为了实现这一目标，提出以下目标。目标 1：开发一种技术，为 PTX 纳米晶体的大规模生产铺平道路。目标 2：表征 PTX 纳米晶体的药物动力学、生物分布和动物急性毒性。目标3：建立靶向PTX纳米晶，进一步提高抗肿瘤效率。我们相信该项目的成功将加速这种纳米技术用于癌症治疗的商业化。公共健康相关性：使用新型三相纳米粒子工程（3PNE）技术开发的紫杉醇纳米晶体由于其简单、低毒和成本效益而具有巨大的商业化潜力。该技术降低了药物剂量并提高了疗效。